COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS

CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 20, 2025, before U.S. markets open.

Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN), a company specializing in regenerative and aesthetics medicine, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 20, 2025, before U.S. markets open. The company, known for its innovative non-animal-derived rhCollagen technology for tissue regeneration and medical aesthetics, will provide updates on its financial performance.

Argus Aug 5 session

+0.09% close to close Open Argus

Details

News Market Reaction – CLGN

In the Aug 5 session, CLGN gained 0.09%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REHOVOT, Israel, Aug. 5, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the second quarter on Wednesday, August 20, 2025, before the opening of the U.S. financial markets.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

For more information about CollPlant, visit http://www.collplant.com.

Contacts:

CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: +972-73-2325600
Email: eran@collplant.com 

Investors:
Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com 

Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-date-for-second-quarter-financial-results-302521770.html

SOURCE CollPlant

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will CollPlant Biotechnologies (NASDAQ: CLGN) release Q2 2025 earnings?

CollPlant will release its Q2 2025 financial results on Wednesday, August 20, 2025, before the U.S. financial markets open.

What is CollPlant Biotechnologies' main business focus?

CollPlant specializes in regenerative and aesthetics medicine, developing technologies and products based on non-animal-derived rhCollagen for tissue regeneration and medical aesthetics.

How can investors access CollPlant's Q2 2025 earnings report?

Investors can access CollPlant's Q2 2025 earnings report before the U.S. markets open on August 20, 2025.

What type of technology does CollPlant Biotechnologies use?

CollPlant uses non-animal-derived rhCollagen technology for tissue regeneration and medical aesthetics applications.